The ₹3,395 crore IPO of the Bengaluru-based Anthem Biosciences Ltd (ABL) will open to the general public today and shut on July 16. The price band has been set at ₹540-570 per share. The market lot is 26 shares.
The issue is completely an offer-for-sale (OFS) by promoters Ganesh Sambasivam and Okay Ravindra Chandrappa; investor shareholders Viridity Tone LLP and Portsmouth Applied sciences LLC; and different shareholders comparable to Malay J Barua, Rupesh N Kinekar, Satish Sharma, Prakash Kariabettan, and Okay Ramakrishnan.
The IPO has 35 per cent reservation for retail buyers, 50 per cent for QIBs and 15 per cent for HNIs.
ABL is an innovation-driven and technology-focused CRDMO with totally built-in operations in Bengaluru, spanning throughout drug discovery, improvement and manufacturing. ABL has a distinctive mannequin of built-in new chemical entity (NCE) and new organic entity (NBE) capabilities throughout drug discovery, improvement and business manufacturing, serving a vary of clients, encompassing innovator-focused rising biotech and huge pharmaceutical corporations globally. ABL is one of the youngest and quickest Indian CRDMO corporations to attain a milestone of ₹1,000 crore in income inside 14 years of operations.
Anthem Biosciences has raised ₹1,016 crore from anchor buyers forward of its preliminary share-sale opening for public subscription.
Some of the buyers that participated in the anchor e book are Abu Dhabi Funding Authority, Authorities Pension Fund International, Eastspring Investments, Amundi Funds, PineBridge International Funds and Societe Generale, HDFC MF (MF), ICICI Prudential MF, Axis MF, UTI MF, Quant MF and Motilal Oswal MF, in accordance with a round uploaded on BSE’s web site late night time on Friday. As per the round, the corporate has allotted 1.78 crore fairness shares to 60 funds at ₹570 apiece.
Anthem is a innovation-driven and technology-focused Contract Analysis, Improvement and Manufacturing Group (CRDMO) with totally built-in operations spanning throughout drug discovery, improvement and manufacturing.
It additionally manufactures and sells complicated specialised fermentation-based Energetic Pharmaceutical Elements (APIs), together with probiotics, enzymes, peptides, dietary actives, vitamin analogues and biosimilars.
Sai Life Sciences Ltd, Syngene Worldwide, Suven Life Sciences and Divi’s Laboratories are the listed friends of Anthem Biosciences.
JM Monetary, Citigroup International Markets India, J P Morgan India and Nomura Monetary Advisory and Securities (India) are the book-running lead managers for the issue.
Printed on July 14, 2025
Source link
#Anthem #Biosciences #issue #opens #today #price #band
